Clin Oncol | Volume 2, Issue 1 | Research Article | Open Access

Single Ablative Intravesical Electromotive Mitomycin C Administration for Small Non-Muscle-Invasive Bladder Cancer: A Prospective Study

Karel Decaestecker, Nicolaas Lumen, Christel Van Camp and Willem Oosterlinck*

Department of Urology, Ghent University Hospital, Ghent, Belgium

*Correspondance to: Willem Oosterlinck 

Fulltext PDF


Aim: To explore the effect of Electromotive Drug Administration Of Mitomycin C (EMDA-MMC) using a single dose of intravesical mitomycin C (MMC) to avoid transurethral resection (TURBT) for small non-muscle-invasive bladder cancer. Material and
Methods: All patients presenting small papillary bladder tumors were proposed to undergo a single EMDA-MMC session with 60mg MMC before planning TURBT. The end point is complete disappearance of all papillary tumors at 2 to 4 weeks after EMDA-MMC.Results: Thirty-six sessions were given to 32 patients. In general the treatment was well supported, except for two patients who had severe bladder spasms, resulting in early evacuation of the MMC. Complete response occurred in 28% (10/36 sessions). In 4 sessions with multiple tumors some tumors disappeared while others remained. In 61% (22/36) the tumors remained unchanged.
Conclusion: A single EMDA-MMC in small papillary bladder tumors gives insufficient ablative effect.


Electromotive drug administration; Mitomycin; Intravesical chemotherapy; Urothelial bladder cancer; Chemoresection; Superficialbladder tumors; Non-muscle-invasivebladder cancer


Decaestecker K, Lumen N, Van Camp C, Oosterlinck W. Single Ablative Intravesical Electromotive Mitomycin C Administration for Small Non-Muscle- Invasive Bladder Cancer: A Prospective Study. Clin Oncol. 2017; 2: 1253.

Subscribe to Our Newsletter